Skip to content

Results from a clinical study with the DEX implant 0.7mg demonstrates significant improvement in visual function

Researchers from University College London’s Institute of Ophthalmology and Moorfields Eye Hospital, in collaboration with Allergan, Inc., have published results evaluating the effect of a single treatment with dexamethasone intravitreal implant (DEX implant) on patient-reported visual functioning in noninfectious intermediate or posterior uveitis. The vision outcome study data, based on the Phase III multicenter masked, randomized, sham-controlled, parallel group trial of 0.70 and 0.35 mg DEX implant (compared with a sham procedure), showed that the treatment group had clinically significant improvements as early as week eight which were maintained out to week 26.